Steris's revenue was $5.94bn in fiscal 2026, up 8.7% on the year before. Since fiscal 2017 ($2.61bn) it has grown at a compound 9.5% a year. Over the last twelve months it was $6.04bn.
Revenue history
US$ millions unless shown otherwise.
Fiscal years, plus the last twelve months (LTM) when newer.
Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.
Where the revenue comes from
Fiscal year to March 31, 2026
Healthcare$4.2B
Applied Sterilization Technologies$1.1B
Life Science Member$589M
Segments
Line of business
Revenue
Share
YoY
Healthcare
$4.2B
70.9%
▲ 8.5%
Applied Sterilization Technologies
$1.1B
19.2%
▲ 9.6%
Life Science Member
$589M
9.9%
▲ 8.6%
Products$3.1B
Services$2.9B
Products and services
Line of business
Revenue
Share
YoY
Products
$3.1B
51.6%
▲ 6.6%
Services
$2.9B
48.4%
▲ 11.1%
United States$4.3B
Otherforeignlocations$1.5B
Ireland$109M
Geography
Region
Revenue
Share
YoY
United States
$4.3B
73.0%
▲ 8.1%
Otherforeignlocations
$1.5B
25.2%
▲ 11.1%
Ireland
$109M
1.8%
▲ 1.1%
From Steris's 10-K filed May 29, 2026, as tagged in the filing.
View filing. Indented rows are part of the
line above; their share is of that line. In the bars, the
faint bar behind is the year before.
Revenue against peers
Health Care Equipment: the closest covered companies by revenue. Last twelve months.
Figures from Steris's SEC filings (10-K and 10-Q), retrieved October 20, 2026.
How we read and check them: methodology and data sources.
Not investment advice. Back to Steris.
